{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:39:52Z","timestamp":1789544392619,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700187"],"award-info":[{"award-number":["81700187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Henan Medical Science and Technology Research Project","award":["2021-KY-1173-082"],"award-info":[{"award-number":["2021-KY-1173-082"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00432-022-04321-6","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T09:02:21Z","timestamp":1661677341000},"page":"3989-4003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China"],"prefix":"10.1007","volume":"149","author":[{"given":"Qing","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huting","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,28]]},"reference":[{"key":"4321_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/17474086.2016.1235970","volume":"9","author":"PB Allen","year":"2016","unstructured":"Allen PB, Gordon LI (2016) PD-1 blockade in Hodgkin\u2019s lymphoma: learning new tricks from an old teacher. Expert Rev Hematol 9:939\u2013949. https:\/\/doi.org\/10.1080\/17474086.2016.1235970","journal-title":"Expert Rev Hematol"},{"key":"4321_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","volume":"134","author":"P Armand","year":"2019","unstructured":"Armand P, Chen YB, Redd RA et al (2019) PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood 134:22\u201329. https:\/\/doi.org\/10.1182\/blood.2019000215","journal-title":"Blood"},{"key":"4321_CR3","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","volume":"127","author":"B B\u00f6ll","year":"2016","unstructured":"B\u00f6ll B, Goergen H, Behringer K et al (2016) Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 127:2189\u20132192. https:\/\/doi.org\/10.1182\/blood-2015-11-681064","journal-title":"Blood"},{"key":"4321_CR4","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/s0140-6736(20)32207-8","volume":"398","author":"P Brice","year":"2021","unstructured":"Brice P, de Kerviler E, Friedberg JW (2021) Classical Hodgkin lymphoma. Lancet 398:1518\u20131527. https:\/\/doi.org\/10.1016\/s0140-6736(20)32207-8","journal-title":"Lancet"},{"key":"4321_CR5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","volume":"6","author":"PJ Br\u00f6ckelmann","year":"2020","unstructured":"Br\u00f6ckelmann PJ, Goergen H, Keller U et al (2020) Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial. JAMA Oncol 6:872\u2013880. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0750","journal-title":"JAMA Oncol"},{"key":"4321_CR6","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/nejm199211193272102","volume":"327","author":"GP Canellos","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ et al (1992) Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478\u20131484. https:\/\/doi.org\/10.1056\/nejm199211193272102","journal-title":"N Engl J Med"},{"key":"4321_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1200\/jco.2003.12.086","volume":"21","author":"DB Duggan","year":"2003","unstructured":"Duggan DB, Petroni GR, Johnson JL et al (2003) Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin\u2019s disease: report of an intergroup trial. J Clin Oncol 21:607\u2013614. https:\/\/doi.org\/10.1200\/jco.2003.12.086","journal-title":"J Clin Oncol"},{"key":"4321_CR8","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1182\/blood.2019004044","volume":"136","author":"DA Eichenauer","year":"2020","unstructured":"Eichenauer DA, Engert A (2020) How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood 136:2987\u20132993. https:\/\/doi.org\/10.1182\/blood.2019004044","journal-title":"Blood"},{"key":"4321_CR9","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1200\/jco.2005.11.080","volume":"23","author":"A Engert","year":"2005","unstructured":"Engert A, Ballova V, Haverkamp H et al (2005) Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group. J Clin Oncol 23:5052\u20135060. https:\/\/doi.org\/10.1200\/jco.2005.11.080","journal-title":"J Clin Oncol"},{"key":"4321_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","volume":"119","author":"AM Evens","year":"2012","unstructured":"Evens AM, Helenowski I, Ramsdale E et al (2012) A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 119:692\u2013695. https:\/\/doi.org\/10.1182\/blood-2011-09-378414","journal-title":"Blood"},{"key":"4321_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/hematology.2019000028","volume":"2019","author":"AM Evens","year":"2019","unstructured":"Evens AM, Carter J, Loh KP et al (2019) Management of older Hodgkin lymphoma patients. Hematology Am Soc Hematol Educ Program 2019:233\u2013242. https:\/\/doi.org\/10.1182\/hematology.2019000028","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"4321_CR12","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3324\/haematol.11502","volume":"92","author":"M Federico","year":"2007","unstructured":"Federico M, Guglielmi C, Luminari S et al (2007) Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL Study. Haematologica 92:1482\u20131488. https:\/\/doi.org\/10.3324\/haematol.11502","journal-title":"Haematologica"},{"key":"4321_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.critrevonc.2012.12.003","volume":"87","author":"M Froudarakis","year":"2013","unstructured":"Froudarakis M, Hatzimichael E, Kyriazopoulou L et al (2013) Revisiting bleomycin from pathophysiology to safe clinical use. Crit Rev Oncol Hematol 87:90\u2013100. https:\/\/doi.org\/10.1016\/j.critrevonc.2012.12.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"4321_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00277-016-2611-4","volume":"95","author":"A Jalali","year":"2016","unstructured":"Jalali A, Ha FJ, Chong G et al (2016) Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Ann Hematol 95:809\u2013816. https:\/\/doi.org\/10.1007\/s00277-016-2611-4","journal-title":"Ann Hematol"},{"key":"4321_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/17474086.2017.1281122","volume":"10","author":"M Jiang","year":"2017","unstructured":"Jiang M, Bennani NN, Feldman AL (2017) Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms. Expert Rev Hematol 10:239\u2013249. https:\/\/doi.org\/10.1080\/17474086.2017.1281122","journal-title":"Expert Rev Hematol"},{"key":"4321_CR16","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1517\/14740338.2014.946901","volume":"13","author":"\u00c1 J\u00f3na","year":"2014","unstructured":"J\u00f3na \u00c1, Milt\u00e9nyi Z, Ujj Z et al (2014) Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity. Expert Opin Drug Saf 13:1291\u20131297. https:\/\/doi.org\/10.1517\/14740338.2014.946901","journal-title":"Expert Opin Drug Saf"},{"key":"4321_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hon.2589","volume":"37","author":"AS LaCasce","year":"2019","unstructured":"LaCasce AS (2019) Treating Hodgkin lymphoma in the new millennium: relapsed and refractory disease. Hematol Oncol 37:87\u201391. https:\/\/doi.org\/10.1002\/hon.2589","journal-title":"Hematol Oncol"},{"key":"4321_CR18","doi-asserted-by":"publisher","first-page":"7614","DOI":"10.1200\/jco.2005.02.7243","volume":"23","author":"WG Martin","year":"2005","unstructured":"Martin WG, Ristow KM, Habermann TM et al (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma. J Clin Oncol 23:7614\u20137620. https:\/\/doi.org\/10.1200\/jco.2005.02.7243","journal-title":"J Clin Oncol"},{"key":"4321_CR19","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1200\/jco.2017.72.2611","volume":"35","author":"RM Meyer","year":"2017","unstructured":"Meyer RM (2017) Limited-stage Hodgkin lymphoma: clarifying uncertainty. J Clin Oncol 35:1760\u20131763. https:\/\/doi.org\/10.1200\/jco.2017.72.2611","journal-title":"J Clin Oncol"},{"key":"4321_CR20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.leukres.2015.08.016","volume":"39","author":"K Miyashita","year":"2015","unstructured":"Miyashita K, Tomita N, Taguri M et al (2015) Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy. Leuk Res 39:1187\u20131191. https:\/\/doi.org\/10.1016\/j.leukres.2015.08.016","journal-title":"Leuk Res"},{"key":"4321_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1182\/asheducation-2018.1.207","volume":"2018","author":"AJ Moskowitz","year":"2018","unstructured":"Moskowitz AJ (2018) Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy. Hematology Am Soc Hematol Educ Program 2018:207\u2013212. https:\/\/doi.org\/10.1182\/asheducation-2018.1.207","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"4321_CR22","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1182\/blood.2020009281","volume":"137","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ (2021) PD-1 blockade for untreated Hodgkin lymphoma. Blood 137:1271\u20131272. https:\/\/doi.org\/10.1182\/blood.2020009281","journal-title":"Blood"},{"key":"4321_CR23","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","volume":"131","author":"A Mottok","year":"2018","unstructured":"Mottok A, Steidl C (2018) Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood 131:1654\u20131665. https:\/\/doi.org\/10.1182\/blood-2017-09-772632","journal-title":"Blood"},{"key":"4321_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12032-014-0185-3","volume":"31","author":"Y Nakajima","year":"2014","unstructured":"Nakajima Y, Tomita N, Watanabe R et al (2014) Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy. Med Oncol 31:185. https:\/\/doi.org\/10.1007\/s12032-014-0185-3","journal-title":"Med Oncol"},{"key":"4321_CR25","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","volume":"5","author":"VM Orellana-Noia","year":"2021","unstructured":"Orellana-Noia VM, Isaac K, Malecek MK et al (2021) Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. Blood Adv 5:3623\u20133632. https:\/\/doi.org\/10.1182\/bloodadvances.2021004645","journal-title":"Blood Adv"},{"key":"4321_CR26","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/jco.19.00315","volume":"37","author":"R Ramchandren","year":"2019","unstructured":"Ramchandren R, Domingo-Dom\u00e8nech E, Rueda A et al (2019) Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II checkmate 205 study. J Clin Oncol 37:1997\u20132007. https:\/\/doi.org\/10.1200\/jco.19.00315","journal-title":"J Clin Oncol"},{"key":"4321_CR27","volume-title":"Etoposide","author":"G Reyhanoglu","year":"2022","unstructured":"Reyhanoglu G, Tadi P (2022) Etoposide. StatPearls Publishing, Treasure Island (FL)"},{"key":"4321_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.clml.2020.08.018","volume":"21","author":"A Rose","year":"2021","unstructured":"Rose A, Grajales-Cruz A, Lim A et al (2021) Classical Hodgkin lymphoma: clinicopathologic features, prognostic factors, and outcomes from a 28-Year single institutional experience. Clin Lymphoma Myeloma Leuk 21:132\u2013138. https:\/\/doi.org\/10.1016\/j.clml.2020.08.018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4321_CR29","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/jco.2016.70.9410","volume":"35","author":"S Sasse","year":"2017","unstructured":"Sasse S, Br\u00f6ckelmann PJ, Goergen H et al (2017) Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials. J Clin Oncol 35:1999\u20132007. https:\/\/doi.org\/10.1200\/jco.2016.70.9410","journal-title":"J Clin Oncol"},{"key":"4321_CR30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000460819","volume":"40","author":"RG Shafi","year":"2017","unstructured":"Shafi RG, Al-Mansour MM, Kanfar SS et al (2017) Hodgkin lymphoma outcome: a retrospective study from 3 tertiary centers in Saudi Arabia. Oncol Res Treat 40:288\u2013292. https:\/\/doi.org\/10.1159\/000460819","journal-title":"Oncol Res Treat"},{"key":"4321_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.drudis.2008.11.001","volume":"14","author":"C Shi","year":"2009","unstructured":"Shi C, Zhu Y, Su Y et al (2009) Beta2-microglobulin: emerging as a promising cancer therapeutic target. Drug Discov Today 14:25\u201330. https:\/\/doi.org\/10.1016\/j.drudis.2008.11.001","journal-title":"Drug Discov Today"},{"key":"4321_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/1078155215574294","volume":"22","author":"BM Shippee","year":"2016","unstructured":"Shippee BM, Bates JS, Richards KL (2016) The role of screening and monitoring for bleomycin pulmonary toxicity. J Oncol Pharm Pract 22:308\u2013312. https:\/\/doi.org\/10.1177\/1078155215574294","journal-title":"J Oncol Pharm Pract"},{"key":"4321_CR33","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/s1470-2045(13)70341-3","volume":"14","author":"N Skoetz","year":"2013","unstructured":"Skoetz N, Trelle S, Rancea M et al (2013) Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2019s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 14:943\u2013952. https:\/\/doi.org\/10.1016\/s1470-2045(13)70341-3","journal-title":"Lancet Oncol"},{"key":"4321_CR34","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1080\/10428194.2019.1594212","volume":"60","author":"M Sorigue","year":"2019","unstructured":"Sorigue M, Bishton M, Domingo-Domenech E et al (2019) Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. Leuk Lymphoma 60:2524\u20132531. https:\/\/doi.org\/10.1080\/10428194.2019.1594212","journal-title":"Leuk Lymphoma"},{"key":"4321_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/bjh.13419","volume":"170","author":"A Stamatoullas","year":"2015","unstructured":"Stamatoullas A, Brice P, Bouabdallah R et al (2015) Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 170:179\u2013184. https:\/\/doi.org\/10.1111\/bjh.13419","journal-title":"Br J Haematol"},{"key":"4321_CR36","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/s2352-3026(21)00102-2","volume":"8","author":"DJ Straus","year":"2021","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Connors JM et al (2021) Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 8:e410\u2013e421. https:\/\/doi.org\/10.1016\/s2352-3026(21)00102-2","journal-title":"Lancet Haematol"},{"key":"4321_CR37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.14735\/amko2016295","volume":"29","author":"A S\u00fdkorov\u00e1","year":"2016","unstructured":"S\u00fdkorov\u00e1 A, Pytl\u00edk R, M\u00f3cikov\u00e1 H et al (2016) Staging and treatment response evaluation in malignant lymphomas\u2014Czech lymphoma study group recommendations according to criteria revised in 2014 (Lugano classification). Klin Onkol 29:295\u2013302. https:\/\/doi.org\/10.14735\/amko2016295","journal-title":"Klin Onkol"},{"key":"4321_CR38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/10428194.2019.1663419","volume":"61","author":"K Taparra","year":"2020","unstructured":"Taparra K, Liu H, Polley MY et al (2020) Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leuk Lymphoma 61:298\u2013308. https:\/\/doi.org\/10.1080\/10428194.2019.1663419","journal-title":"Leuk Lymphoma"},{"key":"4321_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jgo.2019.09.009","volume":"11","author":"TS Thomas","year":"2020","unstructured":"Thomas TS, Luo S, Reagan PM et al (2020) Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin lymphoma. J Geriatr Oncol 11:69\u201374. https:\/\/doi.org\/10.1016\/j.jgo.2019.09.009","journal-title":"J Geriatr Oncol"},{"key":"4321_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1634\/theoncologist.2018-0045","volume":"24","author":"S Vardhana","year":"2019","unstructured":"Vardhana S, Cicero K, Velez MJ et al (2019) Strategies for recognizing and managing immune-mediated adverse events in the treatment of Hodgkin lymphoma with checkpoint inhibitors. Oncologist 24:86\u201395. https:\/\/doi.org\/10.1634\/theoncologist.2018-0045","journal-title":"Oncologist"},{"key":"4321_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","volume":"365","author":"S Viviani","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A et al (2011) ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. N Engl J Med 365:203\u2013212. https:\/\/doi.org\/10.1056\/NEJMoa1100340","journal-title":"N Engl J Med"},{"key":"4321_CR42","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1016\/s2352-3026(18)30140-6","volume":"5","author":"B von Tresckow","year":"2018","unstructured":"von Tresckow B, Kreissl S, Goergen H et al (2018) Intensive treatment strategies in advanced-stage Hodgkin\u2019s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol 5:e462\u2013e473. https:\/\/doi.org\/10.1016\/s2352-3026(18)30140-6","journal-title":"Lancet Haematol"},{"key":"4321_CR43","doi-asserted-by":"publisher","first-page":"72219","DOI":"10.18632\/oncotarget.12663","volume":"7","author":"Q Wang","year":"2016","unstructured":"Wang Q, Qin Y, Zhou S et al (2016) Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. Oncotarget 7:72219\u201372228. https:\/\/doi.org\/10.18632\/oncotarget.12663","journal-title":"Oncotarget"},{"key":"4321_CR44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68\u201383. https:\/\/doi.org\/10.1182\/blood-2017-07-740993","journal-title":"Blood"},{"key":"4321_CR45","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/s1470-2045(16)30167-x","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283\u20131294. https:\/\/doi.org\/10.1016\/s1470-2045(16)30167-x","journal-title":"Lancet Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04321-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04321-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04321-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:15:23Z","timestamp":1688213723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04321-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,28]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4321"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04321-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,28]]},"assertion":[{"value":"21 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Scientific Research\/Medicine Clinical Trial of The First Affiliated Hospital of Zhengzhou University (Approval No. 2022-KY-0869; Zhengzhou, China).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}